Epigenetic Alterations in Depression and Treatment Perspectives


DNA methylation modifications
Histone modifications
Non-coding RNA regulation
Therapeutic perspectives




The global incidence of depression is progressively on the rise and tends to occur more in younger generations, however the pathogenesis of the disease is unclear. Meanwhile, epigenetics is a modification which produces heritable alterations in the DNA sequence, which ultimately manifest in phenotypic differences. It has been suggested that the onset and development of depression can be tentatively explained by the combination of epigenetic and environmental factors. This paper reviews epigenetic changes in depression in the context of environmental factors, including DNA methylation modifications, histone modifications, and non-coding RNA regulation.  An epigenetic-based therapeutic outlook was also proposed in this paper, which initially elucidates the epigenetic mechanisms underlying the pathogenesis of depressions and provides a theoretical basis for the treatment of depression.


Xu N, Zhang G, 2016, Research Progress on Epigenetic Mechanisms of Depression. Journal of Graduate Medical Science, 29(10): 1093–1096.

Zhang K, Zhao M, Lin W, 2016, The Role of Epigenetic Modifications in Stress-Induced Depression. Advances in Psychological Science, 24(12): 1882–1888.

Yang Z, Bao J, Zhang X, 2018, The Effects of DNA Methylation on the Development of Psychiatric Disorders. Gansu Medicine, 37(2): 100–104.

Li Z, Li N, Zeng Y, 2020, Role and Mechanism of DNA Epigenetic Modifications in Depression. Chemistry of Life, 40(7): 1093–1099.

Li S, Fu W, 2021, Advances in the Study of Epigenetic Alterations in Depression. Anatomical Medical Research, 43(3): 272276.

Zhao Z, Bao J, 2019, The Role of Epigenetic Modifications in the Development of Depression. Advances in Physiological Sciences, 50(5): 339–342.

Guo W, Jin L, Li L, 2020, Depression with Childhood Trauma: Clinical Features, Biological Mechanisms, and Therapeutic Insights. Journal of Central South University, 45(4): 462–468.

Yao K, Ding H, Zeng L, 2021, Antidepressant Prospects of Histone Deacetylase Inhibitors. Journal of Pharmacology, 56(1): 29–36.

Eyding D, Lelgemann M, Grouven U, et al., 2010, Reboxetine for Acute Treatment of Major Depression: Systematic Review and Meta-Analysis of Published and Unpublished Placebo and Selective Serotonin Reuptake Inhibitor Controlled Trials. BMJ Open, 341: c4737.

Huang L, Chen Y, Zhao B, 2018, Causes of Depression and its New Drug Research Progress. Advances in Modern Biomedicine, 18(1): 180–185.